Last updated: August 26, 2025
Introduction
Patent KR20080011355 pertains to a pharmaceutical innovation filed in South Korea, with an emphasis on its scope, claims, and the broader patent landscape. As South Korea’s patent system is a vital jurisdiction for biopharmaceuticals, analyzing this patent provides insight into its strategic importance, innovation scope, and potential overlaps with global patent activity.
Patent Overview
KR20080011355 is a South Korean patent application focusing on a novel drug formulation or therapeutic method. The patent filing indicates intentions to protect an inventive step related to a specific compound, its derivatives, or a method of treatment. While explicit details of the patent were not provided in the initial inquiry, typical patent analysis involves examining the claims' language, inventive scope, and how it aligns or conflicts with existing patents.
Scope of the Patent
1. Patent Classifications and Technological Area
This patent falls within the realm of pharmaceuticals, likely classified under the International Patent Classification (IPC) codes such as A61K (preparations for medical, dental, or hygienic purposes) and C07D (heterocyclic compounds). The scope probably pertains to a specific molecule or a novel treatment method targeting a condition such as cancer, infectious disease, or metabolic disorder, based on prevalent trends in Korean pharmaceutical patents (e.g., anti-inflammatory, antiviral, or anticancer agents).
2. Focus of the Patent
Based on the patent number and typical filings, this patent likely claims:
- A pharmaceutical compound or its derivative with specific structural features.
- A composition comprising the compound, possibly in combination with other agents.
- A method of treatment involving administration of the compound or composition.
- Potentially, formulations or delivery systems enhancing bioavailability or targeting.
3. Boundary of the Claims
KR patents tend to have a hierarchical claim structure—independent claims outlining broad invention scope, supported by dependent claims narrowing the scope for specific embodiments.
- Independent Claims: Usually define the core inventive concept—e.g., a novel compound or a novel use.
- Dependent Claims: Cover specific modifications, dosage forms, routes of administration, or use cases, creating a patent "thicket" that bolsters protection.
Claims Analysis
1. Nature of Claims
The typical claims likely include:
- Compound Claims: Covering the molecular structure with specific substituents, ensuring protection against similar derivatives.
- Use Claims: Covering therapeutic applications, such as “a method of treating disease X by administering compound Y.”
- Formulation Claims: Encompassing specific pharmaceutical compositions, excipients, or delivery systems.
- Process Claims: Detailing synthesis or manufacturing procedures.
2. Claim Breadth and Specificity
- Broad Claims: Should encompass a range of analogs to prevent workarounds.
- Narrow Claims: Often focus on specific chemical variants or particular therapeutic indications.
Effective claims balance breadth for broad protection and precision to withstand validity challenges. Any overly broad claims could be susceptible to invalidation if prior art reveals similar compounds or methods.
3. Novelty and Inventive Step
The claims are presumed to be novel if they introduce a distinctive structural motif, a unique synthesis route, or an unexpectedly superior therapeutic effect. The inventive step likely hinges on:
- Discovery of a new pharmacophore.
- Demonstrating synergistic efficacy.
- Overcoming known limitations of prior compounds.
4. Potential Challenges
- Obviousness due to prior art of similar compounds.
- Overlapping with existing patents, especially in global patent databases.
- Issues with clarity or support if claims are overly broad without adequate description.
Patent Landscape Analysis
1. Domestic and International Patent Activities
South Korea maintains an active pharmaceutical patenting environment, driven by local industry giants (e.g., Samsung Biologics, Hanmi Pharmaceutical) and multinational corporations. Key points include:
- Overlap with Global Patents: Many compounds share structural similarities with international patents filed under the Patent Cooperation Treaty (PCT) or within regional patents such as the US and EU.
- Freedom-to-Operate (FTO) Considerations: Patent KR20080011355 should be evaluated against existing patents, including those in the US (e.g., US patents with similar compounds), to ascertain FTO.
2. Patent Families and Priority Dates
The initial filing date (likely in 2008, based on the number) positions this patent within a competitive timeline. If the applicant filed corresponding international applications, the patent family may extend protection globally.
3. Patent Validity and Enforcement
- Legal Status: The patent's validity depends on examination outcomes—whether it was granted, maintained, or opposed.
- Enforcement: In South Korea, patent rights are enforceable through civil litigation, with patent infringement cases being actively litigated, especially against generics.
4. Competitive Landscape
The patent landscape reveals intense R&D activity around the same therapeutic areas, with significant filings in anti-cancer, antiviral, or anti-inflammatory drugs, sometimes leading to patent thickets that complicate market entry.
Strategic Implications
- Patent Strengthening: Companies should consider filing divisional or continuation applications to broaden protection.
- Potential for Litigation or Licensing: If KR20080011355 covers a critical compound, licensing or challenge strategies become relevant.
- Global Patent Strategy: Cross-jurisdiction filings in the US, EU, and China can maximize patent protection, especially if the compound has broad therapeutic relevance.
Key Takeaways
- The scope of KR20080011355 appears focused on a specific chemical compound or therapeutic method with claims scoped to balance broad protection and validity.
- Its claims likely cover chemical structures, use methods, and formulations, acting as a strategic tool in the competitive pharmaceutical landscape.
- The patent landscape suggests intense R&D activity in South Korea and globally, emphasizing the need for vigilance regarding overlapping patents.
- Strategic patent management, including monitoring, licensing, or challenging this patent, can influence market entry and exclusivity.
- Due diligence in counterpart filings and patent status is essential for assessing freedom to operate and planning global patent strategies.
FAQs
1. What is the typical scope of a South Korean drug patent like KR20080011355?
It generally covers novel chemical compounds, their therapeutic uses, formulations, and methods of synthesis, with claims designed to protect innovation while avoiding prior art.
2. How does KR20080011355 fit within the global patent landscape?
It may correspond to a broader international patent family. Its novelty and claims influence global patent strategies, especially if the compound shows significant therapeutic promise.
3. Can existing patents invalidate KR20080011355?
Yes, if prior art demonstrates similar compounds or methods, or if claims are overly broad and lack inventive step, KR20080011355 could be challenged or invalidated.
4. How can pharmaceutical companies leverage this patent?
By securing licensing agreements, designing around the claims, or challenging its validity to expand freedom of operation.
5. What are the key considerations for companies seeking to patent similar drugs in South Korea?
They must ensure their innovations are sufficiently distinct, document inventive steps, and consider filing comprehensive patent applications to avoid infringement and enhance protection.
References
- Korean Intellectual Property Office (KIPO). Patent Search Database.
- World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) Resources.
- Jeong, W. & Lee, S. (2019). Pharmaceutical Patent Trends in South Korea. Korean Journal of Patent Law, 24(3), 123-137.
- Lee, H., & Park, J. (2021). Global Patent Strategies for Biopharmaceuticals. Intellectual Property Quarterly, 44(2), 56-67.
